Aerovate Therapeutics (NASDAQ:AVTE) Posts Earnings Results, Beats Estimates By $0.03 EPS

Aerovate Therapeutics (NASDAQ:AVTE) released its quarterly earnings data on Tuesday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.03, Zacks reports.

Aerovate Therapeutics Trading Down 0.4 %

AVTE stock traded down $0.01 during trading on Thursday, hitting $2.62. The company had a trading volume of 74,888 shares, compared to its average volume of 616,882. Aerovate Therapeutics has a one year low of $1.25 and a one year high of $32.42. The business has a 50-day moving average of $2.18 and a 200-day moving average of $6.33. The stock has a market cap of $75.64 million, a PE ratio of -0.88 and a beta of 1.00.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.